Business Daily from THE HINDU group of publications
Sunday, Jun 22, 2008
ePaper | Mobile/PDA Version | Audio


Investment World
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Alternative Medicines
Investment World - Interview
‘The nutraceutical industry is at varying levels of maturity’


Despite being a billion-dollar industry, there are not too many players, especially large ones. This means early entry into herbals and nutraceuticals would generate higher returns in the medium term.




MR SHASHIKANT PATEL, CMD, PLETHICO PHARMACEUTICALS.

Kumar Shankar Roy
Advertisement

While most Indian pharma companies focus on the US generics or the contract manufacturing business, Plethico Pharmaceuticals is betting on herbals and nutraceuticals. Mr Shashikant Patel, Chairman and Managing Director, shares his views with Business Line in an email interview on a host of issues. We kick off by asking the Plethico boss what makes him believe that nutraceuticals are the next ‘big’ thing…

Edited excerpts from the interview:

Unlike many pharma players who are fighting for the export opportunity in generics or CRAMS (contract research and manufacturing), why have you focussed on herbals and nutraceuticals?

You are absolutely right that Plethico is today focusing on herbals and nutraceuticals. This is a contrarian approach but our financial performance is reflective of our achievements in this segment. We believe our acquisition of Natrol is only going to fortify our view on this industry.

Why we chose to enter this industry? Despite being a billion-dollar industry, there are not too many players, especially large ones. This means that it is a sunrise industry which, if entered early, would generate higher returns in the medium term.

In 1997, when we took the decision to focus on herbals and nutraceuticals, we were an unlisted entity with limited resources, so a pure play of research was not possible. After we tasted success in the herbal sector with the launch of Travisil post-1998, it fortified our view on the way forward in this industry.

How is the over-the-counter healthcare market in India?

The OTC healthcare market in India is estimated to be around a billion dollars with major contributors being food supplements and health food which account for $400 million. Today, Plethico is in the field of ‘Sports Nutrition’, ‘Confectionary’ and ‘Herbal OTC’ in India.

Are consumers using nutraceuticals as much as you would want them?

Nutraceutical is a very wide term and we have already described the segment that we are in today. The selectable consumer profile in India today is typically a member of a joint family, no scope/time for grandmother remedies, inclined to take scientifically proven medication, believes in preventive medicine and is increasingly aware of health-related issues due to hectic lifestyle and food habits.

The company we acquired, Natrol, gives us a basket of herbal generics and food supplements which actually target this typical consumer. I must admit, today the proportion of above is not even 5 per cent of the overall population. But the fact is that this strata is growing. The strategy to target customers would entail a gestation period after which the benefits would start showing as the consumer will begin taking supplements.

What does your US acquisition, of Natrol Inc, bring on the table for you?

We acquired Natrol with a clear understanding that the bad patch is over and that the company would turnaround quickly. Before the acquisition we were assured an EBITDA of 10 per cent at least, which currently stands at almost 13 per cent.

Even if one is to keep aside the financial aspect of Natrol, the real cutting edge is we have a head-start on nutraceuticals in the US. We have a retail reach of more than 60,000 stores, selling to the likes of Walgreen, Wal-Mart, CVS, Riteaid, Costco, GNC stores, etc. We also got manufacturing facilities which already complies with the new guidelines issued in the US for nutraceuticals.

Last but not the least, we have got an experienced and professional management which will continue to run the company. Plethico is focusing on Natrol to make up for weakness of very less exposure to semi-regulated markets which are our stronghold.

What are your top brands and what has been the revenue contribution to your revenues?

The top five range of products for Plethico are Travisil, Therasil, Mountain Herbz, Coach’s formula and Effertabs. These are expected to contribute more than 50 per cent of our revenues, apart from contract manufacturing/toll manufacturing (CM/TM) contributing almost 25 per cent of total revenues.

Plethico is in the process of putting up a manufacturing plant in Dubai. Is the Gulf Cooperation Council market so important?

The Dubai unit of Lozenges is meant for all advanced markets such as the US, the UK, Europe and also the CIS. The Indian unit will used to cater to the domestic and South-East Asian markets. The GCC will also be catered to from Dubai. GCC is an important market to us because Plethico as well as Natrol products are doing/will do well here. The pricing is very attractive but marketing and related expenses are very high unlike in the CIS, where EBITDA margins are much more attractive.

Outside India, the nutraceuticals market is huge. How is Plethico planning to carve out a position there?

‘Nutraceuticals’ is a broad term that includes foods, dietary supplements, and medical foods offering health/medical benefits, including the prevention and/or treatment of disease. A nutraceutical can also be defined as a food that positively impacts an individual’s health, physical performance or state of mind.

Thus, a nutraceutical is a product with a functional ingredient that provides specific nutritional benefit. The global nutraceuticals market, comprising two principal segments — dietary supplements and functional foods — is poised to grow at a compounded annual growth rate (CAGR) of 6.1 per cent during 2000-2010. Sales of nutraceuticals are projected to reach $187.4 billion by 2010 against an estimated $155.9 billion in 2007.

Factors driving the market include growing consumer interest in a healthy diet and lifestyle, rising healthcare costs, and an aging population. The US represents the largest market worldwide for nutraceuticals, with an estimated sales figure of $50 billion in 2007. Asia-Pacific too is expected to witness fast growth through 2015, reflecting rising consumer income levels, increasing per capita consumption of nutritional products and growing investment in both bulk and end-use product industries.

As a company, Plethico through it’s acquisition in Natrol US, spreading the same to our stronghold markets of CIS, South-East Asia, GCC, and Africa would help take things forward. This is a high focus area for the Plethico sales team.

What are the major factors that would drive the nutraceuticals market, both in India and abroad?

The nutraceutical industry is witnessing varying levels of maturity in different regional markets and serves divergent consumer groups and education levels. However, many regional markets share common growth drivers in various aspects.

The largest regional markets for nutraceuticals include the US, followed by Europe and Japan. Aging population, growing healthcare spending, and rising interest towards self-medication and preventive healthcare have been the key market drivers in these markets.

Sales in other markets, including Asia-Pacific and Latin America, are driven by economic growth, growing disposable incomes and an expanding middle-class. The nutraceuticals industry is likely to witness healthy growth rates in these markets in medium-to-long run.

Plethico is today present in the US, the UK, the GCC and the South-East Asian markets. So as far as nutraceuticals is concerned, we are well entrenched.

Do you feel threatened by the presence of large global food companies that have set up functional food or nutraceutical divisions?

The large conglomerates are slowly realising the changing consumer preferences, which could also be a reason which had influenced the changed FDA stand on quality parameters in the US starting June 2008. There is news that large players are moving into this segment and for growth they will start buying out many small players.

The new changed laws, effective from June, would render many small players open to such attempts. This will clearly lead to consolidation in the nutraceuticals industry and the survival only of the fittest. This is expected to lead to major improvement in the margin game.

As far as Plethico’s approach is concerned, we have not focused on herbal generics sold as food supplements or functional food, but our focus has been on formulations and branding.

How big are factors such as branding are, market promotion and channels for the nutraceuticals market?

Depending on the markets that one is present, the importance of quantum of brand promotion, advertisements and channels would vary. However, one thread remains common to all — branding is of paramount importance irrespective of markets.

Pricing is not a major issue in any of the markets but depending on the market in which one is present, the operational profit gets squeezed because of high marketing costs due to brand promotion or the overbearing proportion of the distribution players such as Walgreen, Wal-Mart, Costco, etc in the US. They derive huge negotiating powers based on their market reach.

In the nutraceuticals market, vitamins have remained a major category. Do you see it changing?

The worldwide market for nutraceutical ingredients is expected to grow rapidly, owing to the availability of clear clinical evidence on safety and health benefits. Additionally, the advent of new applications is expected to push up the demand for essential minerals, magnesium and calcium; herbal extracts green tea and garlic; and soy protein nutrients. Besides, growth would also be witnessed in the functional beverage and food additives such as sterol esters, lutein, probiotics, lycopene and omega-3 fatty acids, and non-herbal extracts such as coenzyme Q10, chondroitin and glucosamine.

What about new areas which are expected to grow in future?

Minerals and nutrients segment is set for rapid growth due to the growing acceptance of health benefits. Consequently, maximum growth is anticipated from broadening applications in functional food and beverages and meal supplements. Other potential growth opportunities are expected from isoflavones and soy proteins, calcium and magnesium, lycopene, probiotics, omega-3 fatty acids and psyllium fibers.

In the nutraceutical vitamin ingredients, natural vitamin E formulations made from non-genetically modified plants would witness the maximum gains due to their acceptance in the EU and other countries such as Brazil that ban food compounds manufactured using biotechnology.

How would you categorise the Chinese competition in the nutraceuticals market?

Changing lifestyles and unbalanced diets are leading to an increase in health-related problems among the general Chinese population. As a result of this, an increasing number of people in China are becoming more health conscious. These factors along with the increase in medical costs are driving the growth of the Chinese nutraceuticals market.

The market is also likely to benefit from the regulations for health food registration that were finalised in 2005 and the ongoing approval of direct sale administrative regulations. Presently, taste, convenience, and style are the major factors influencing the consumers’ purchasing decisions, but health considerations are likely to play a more important role, as consumer awareness of the benefits associated with nutrition to health and well being improves.

As far as margins are concerned, any player with herbal generics would face pressure, whilst players in the formulations especially using traditional Chinese medication (TCM) would stand to gain as there is huge demand to CTM products globally.

Plethico got listed on the stock exchanges in May 2006. Looking back, how do you sum up the progress made by the company?

When we did our IPO, we had stated objectives such as upgrading a plant, spend on R&D unit, getting into organic farming, acquiring an OTC / domestic herbal /nutraceuticals company, amongst others. We were successful in achieving most of them, apart from deferring the acquisition. In October 2007, we acquired Natrol Inc, a NASDAQ listed ‘synergistique herbal nutra’ company for $81 million. So, the company is proud and completely satisfied. Apart from growth and business front, the company is also more strong and bigger by way of strategic moves.

Are not there disconnect between the promises made my manufacturers and the quality delivered by products in this industry?

As far as sports nutrition is concerned there are no regulations put in place by the Government, as such, our products conforms to US Standards (because the major competitors are from the US which also include ‘Prolab’ from Natrol as well). We are in tune with US standards of disclosures and claims on industries front and the US as you know is a regulated market.

As far as confectionary space is concerned, we do not make any claims and finally as far as Herbal OTC is concerned all our claims and quality parameters are strictly as per Pharma line. We test on assay basis the ingredient content level in the finished products, so we are pretty much confident that based on the above, our products are neither stating what is beyond, what is prescribed nor is our quality levels below the norms that we claim it to have. So, we are pretty much in tune with the time and perhaps well ahead of any regulatory requirements in India.

There are concerns that herbal products taken from any two sources are not same…

It is true that herbal products taken from two sources do not necessarily have the same potency. This leads to some concerns of batch to batch variations in efficacy, based on the potency of the material used which, unlike a drug, is completely crystallised formulations which is precise in nature.

But, we saw opportunity here and hence our foray into standardisation for the advanced markets. We clearly believe that with standardisation, consumer education and stringent Government regulation falling into place, it will help the consumer to develop confidence in the products being churned out in today’s market.

What steps have you, as a manufacturer of herbal drugs and nutraceuticals, taken?

Plethico already started the process of putting in place all that a manufacturer has to do to build up consumer confidence and as such our motto is ‘Pledged to Ethics’ which is reflective of what this industry really should be aspiring to achieve.

We are pretty-much compliant on the current regulations and we actually welcome any further stringency in regulations as this will help the industry to consolidate and thus boost the consumer confidence in herbals. This in our opinion is the way forward. The current trends of growing consumer interest in organic foods, functional foods, and dietary supplements are all indicators of what we are focusing on today.

Nutraceuticals-functional food
Sami Labs - pioneer in nutraceuticals
"Nutraceuticals is pharma's future"

More Stories on : Alternative Medicines | Interview | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Hiring

Stories in this Section
Fixed maturity plans: Minimising equity risk at the horizon


HSBC Equity Fund: Invest
Sundaram BNP Paribas India Leadership Fund: Hold
Sundaram BNP Select: Invest
Index Outlook
Maruti Suzuki: Buy
Banking stocks out in the cold
Investing in property — Homing in on taxation issues
Play the market volatility with a long straddle
‘Current valuations are a fund manager’s delight’
Three lessons in computing returns
Somi Conveyor Beltings — IPO: Avoid
KSK Energy Ventures — IPO: Avoid
Vishal Retail: Book profits
‘The nutraceutical industry is at varying levels of maturity’


Life



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line